Home Applications 208255 Application 208255
Type NDA
Sponsor MYLAN Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 SYMFI LO EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE TABLET;ORAL 400MG;300MG;300MG Yes Yes
Source provenance: Browse the complete Orange Book source catalog · source snapshot 44 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N208255-001 SYMFI LO EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE 400MG;300MG;300MG TABLET / ORAL RLD 2018-02-05
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 2 of 2 · 44 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2022-10-28 04:53 UTC 2022-10 N208255-001 SYMFI LO 400MG;300MG;300MG TABLET / ORAL AB RLD, RS 2018-02-05 f41ea6bd6efb…2022-09-29 23:25 UTC 2022-09 N208255-001 SYMFI LO 400MG;300MG;300MG TABLET / ORAL AB RLD, RS 2018-02-05 e64feba35796…2022-07-09 03:26 UTC · 3 captures of this ZIP 2022-07 N208255-001 SYMFI LO 400MG;300MG;300MG TABLET / ORAL AB RLD, RS 2018-02-05 cb3db0bc1861…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N208255-001 SYMFI LO 400MG;300MG;300MG TABLET / ORAL RLD 2018-02-05 a50c72e98297…
Observed Orange Book normalized TE history# Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application# NDC listings for this application page 1 of 1 · 4 matching rows.
NDC, Name, Nonproprietary name table NDC Name Nonproprietary name Labeler Marketing category Status 49502-425 SYMFI LO Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Mylan Specialty L.P. NDA Current 49502-425 SYMFI LO Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Mylan Specialty L.P. NDA Current 49502-425 SYMFI LO Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Mylan Specialty L.P. NDA Current 49502-425 SYMFI LO Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Mylan Specialty L.P. NDA Current
Documents# Document, Submission type, Date table Document Submission type Date 60754 SUPPL 2019-10-31 60728 SUPPL 2019-10-30 55857 ORIG 2018-10-10 52771 ORIG 2018-02-09 52770 ORIG 2018-02-06 62973 ORIG 1900-01-01 62972 ORIG 1900-01-01